TNFRSF17 and plasma cell myeloma: Similarly, patients with R/R LBCL are now approved to receive the CD19‐targeting agents loncastuximab teserine or tafasitimab and R/R myeloma patients may receive the BCMA‐targeting drug belantamab [31, 32, 33].